Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here are two profitable companies that leverage their financial strength to beat the competition and one that may struggle to keep up.
One Stock to Sell:
Post (POST)
Trailing 12-Month GAAP Operating Margin: 9.6%
Founded in 1895, Post (NYSE:POST) is a packaged food company known for its namesake breakfast cereal and healthier-for-you snacks.
Why Should You Sell POST?
- Sales are projected to tank by 5.9% over the next 12 months as demand evaporates
- Gross margin of 29% is below its competitors, leaving less money to invest in areas like marketing and production facilities
- Low returns on capital reflect management’s struggle to allocate funds effectively
Post’s stock price of $72.89 implies a valuation ratio of 10.4x forward P/E. Read our free research report to see why you should think twice about including POST in your portfolio.
Two Stocks to Watch:
Terex (TEX)
Trailing 12-Month GAAP Operating Margin: 5.7%
With humble beginnings as a dump truck company, Terex (NYSE:TEX) today manufactures lifting and material handling equipment designed to move and hoist heavy goods and materials.
Why Does TEX Stand Out?
- Market share has increased this cycle as its 14.1% annual revenue growth over the last five years was exceptional
- Projected revenue growth of 27.6% for the next 12 months is above its two-year trend, pointing to accelerating demand
- Free cash flow margin increased by 6 percentage points over the last five years, giving the company more capital to invest or return to shareholders
At $53.51 per share, Terex trades at 9.8x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Amgen (AMGN)
Trailing 12-Month GAAP Operating Margin: 30%
Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.
Why Are We Fans of AMGN?
- Revenue base of $38.1 billion gives it economies of scale and some negotiating power
- AMGN is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
- Industry-leading 17.3% return on capital demonstrates management’s skill in finding high-return investments
Amgen is trading at $421.81 per share, or 18x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.